EXPLORING NICE CRITERIA FOR CONTINUING BIOLOGIC THERAPIES IN AXIAL SPONDYLOARTHRITIS: WHAT IS A SUBOPTIMAL RESPONSE?

被引：0
|
作者：
Yahya, Fariz [1 ,2 ]
Gaffney, Karl [3 ]
Sengupta, Raj [2 ,4 ]
机构：
[1] Univ Malaya, Med, Med Ctr, Kuala Lumpur, Malaysia
[2] Royal Natl Hosp Rheumat Dis RUH Bath, Rheumatol, Bath, Avon, England
[3] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Rheumatol, Norwich, Norfolk, England
[4] Univ Bath, Pharmacol, Bath, Avon, England
来源：
RHEUMATOLOGY | 2019年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O36
引用
收藏
页码：38 / +
页数：2
相关论文
共 41 条
  • [1] Biologic Therapies for Spondyloarthritis: What Is New?
    Baraliakos, Xenofon
    Braun, Juergen
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2012, 14 (05) : 422 - 427
  • [2] Biologic Therapies for Spondyloarthritis: What Is New?
    Xenofon Baraliakos
    Juergen Braun
    [J]. Current Rheumatology Reports, 2012, 14 : 422 - 427
  • [3] Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
    Jones, Gareth
    Dean, Linda
    Pathan, Ejaz
    Macfarlane, Gary
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [4] Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
    Kiltz, U.
    Baraliakos, X.
    Braun, J.
    van der Heijde, D.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S47 - S50
  • [5] HIGH LEVELS OF EMPLOYMENT BUT PERSISTING WORK IMPAIRMENT IN PATIENTS WITH SEVERE AXIAL SPONDYLOARTHRITIS USING BIOLOGIC THERAPIES
    Nadin, Thomas G.
    Wallis, Dinny
    Holroyd, Christopher
    Clayton, Peter
    Armstrong, Ray
    Cooper, Cyrus
    Davidson, Brian
    Harvey, Nicholas
    Dennison, Elaine
    Seth, Rakhi
    Walker-Bone, Karen E.
    Edwards, Christopher J.
    [J]. RHEUMATOLOGY, 2017, 56 : 88 - 88
  • [6] EXPLORING GENDER DIFFERENCES IN THE CLINICAL PHENOTYPE AND RESPONSE TO TREATMENT IN AXIAL SPONDYLOARTHRITIS
    Gensler, L. S.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 690 - 690
  • [7] DO PATIENTS WITH AXIAL SPONDYLOARTHRITIS WHO MEET RESEARCH CRITERIA FOR FIBROMYALGIA BENEFIT FROM BIOLOGIC THERAPY?
    Macfarlane, Gary J.
    MacDonald, Ross I. R.
    Choy, Ernest
    Packham, Jon
    Siebert, Stefan
    Pathan, Ejaz
    Sengupta, Raj
    Kay, Lesley
    Gaffney, Karl
    Jones, Gareth T.
    [J]. RHEUMATOLOGY, 2018, 57
  • [8] Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
    Marona, Jose
    Sepriano, Alexandre
    Rodrigues-Manica, Santiago
    Pimentel-Santos, Fernando
    Mourao, Ana Filipa
    Gouveia, Nelia
    Branco, Jaime Cunha
    Santos, Helena
    Vieira-Sousa, Elsa
    Vinagre, Filipe
    Tavares-Costa, Joao
    Rovisco, Joao
    Bernardes, Miguel
    Madeira, Nathalie
    Cruz-Machado, Rita
    Roque, Raquel
    Silva, Joana Leite
    Marques, Mary Lucy
    Ferreira, Raquel Miriam
    Ramiro, Sofia
    [J]. RMD OPEN, 2020, 6 (01):
  • [9] CLINICAL RESPONSE TO BIOLOGIC DMARDS IN AXIAL SPONDYLOARTHRITIS AND AXIAL PSORIATIC ARTHRITIS. DIFFERENT DISEASES, SAME OUTCOMES?
    Benavent, D.
    Plasencia, C.
    Franco Gomez, K. N.
    Nuno, L.
    Balsa, A.
    Navarro-Compan, V.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1126 - 1126
  • [10] Amongst patients taking biologic therapies for axial spondyloarthritis, which factors are associated with work non-participation?
    Nadin, Tom
    Wallis, Dinny
    Holroyd, Christopher R.
    D'Angelo, Stefania
    Walker-Bone, Karen
    Edwards, Christopher J.
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2020, 21 (01)
12345